Thermo Fisher Scientific Mogamulizumab Chimeric Recombinant Rabbit Monoclonal Antibody (KW-0761 (Mogamulizumab))

Applications

Product Specifications

Product Specific Information

Specificity: This antibody is specific for human CCR4, a chemokine receptor preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes, and brain microvascular and coronary artery endothelial cells.

Target Information

Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sezary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. These lymphomas occur when certain white blood cells, called T cells, become cancerous, typically affecting the skin and causing various types of lesions.

On August 8, 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use in adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy. Mogamulizumab is derived from Kyowa Hakko Kirin’s POTELLIGENT® technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30, 2012, by the Japanese Ministry of Health, Labor and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.

For Research Use Only.
Not for use in diagnostic procedures. Not for resale without express authorization.